319 related articles for article (PubMed ID: 26216630)
1. Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines.
Palena C; Hamilton DH
Adv Cancer Res; 2015; 128():69-93. PubMed ID: 26216630
[TBL] [Abstract][Full Text] [Related]
2. Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.
Hamilton DH; David JM; Dominguez C; Palena C
Cells Tissues Organs; 2017; 203(2):128-138. PubMed ID: 28214895
[TBL] [Abstract][Full Text] [Related]
3. Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas.
Hamilton DH; Litzinger MT; Fernando RI; Huang B; Palena C
Semin Oncol; 2012 Jun; 39(3):358-66. PubMed ID: 22595058
[TBL] [Abstract][Full Text] [Related]
4. Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine.
Hamilton DH; Litzinger MT; Jales A; Huang B; Fernando RI; Hodge JW; Ardiani A; Apelian D; Schlom J; Palena C
Oncotarget; 2013 Oct; 4(10):1777-90. PubMed ID: 24125763
[TBL] [Abstract][Full Text] [Related]
5. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury.
Heery CR; Palena C; McMahon S; Donahue RN; Lepone LM; Grenga I; Dirmeier U; Cordes L; Marté J; Dahut W; Singh H; Madan RA; Fernando RI; Hamilton DH; Schlom J; Gulley JL
Clin Cancer Res; 2017 Nov; 23(22):6833-6845. PubMed ID: 28855356
[No Abstract] [Full Text] [Related]
6. Identification and characterization of a cytotoxic T-lymphocyte agonist epitope of brachyury, a transcription factor involved in epithelial to mesenchymal transition and metastasis.
Tucker JA; Jochems C; Boyerinas B; Fallon J; Greiner JW; Palena C; Rodell TC; Schlom J; Tsang KY
Cancer Immunol Immunother; 2014 Dec; 63(12):1307-17. PubMed ID: 25186612
[TBL] [Abstract][Full Text] [Related]
7. The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy.
Palena C; Polev DE; Tsang KY; Fernando RI; Litzinger M; Krukovskaya LL; Baranova AV; Kozlov AP; Schlom J
Clin Cancer Res; 2007 Apr; 13(8):2471-8. PubMed ID: 17438107
[TBL] [Abstract][Full Text] [Related]
8. Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer.
Hamilton DH; Roselli M; Ferroni P; Costarelli L; Cavaliere F; Taffuri M; Palena C; Guadagni F
Endocr Relat Cancer; 2016 Oct; 23(10):783-796. PubMed ID: 27580659
[TBL] [Abstract][Full Text] [Related]
9. Understanding Molecular Pathways and Targets of Brachyury in Epithelial-mesenchymal Transition (EMT) in Human Cancers.
Song W; Gobe GC
Curr Cancer Drug Targets; 2016; 16(7):586-93. PubMed ID: 27018266
[TBL] [Abstract][Full Text] [Related]
10. Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness.
Liao TT; Yang MH
Mol Oncol; 2017 Jul; 11(7):792-804. PubMed ID: 28649800
[TBL] [Abstract][Full Text] [Related]
11. Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.
Heery CR; Singh BH; Rauckhorst M; Marté JL; Donahue RN; Grenga I; Rodell TC; Dahut W; Arlen PM; Madan RA; Schlom J; Gulley JL
Cancer Immunol Res; 2015 Nov; 3(11):1248-56. PubMed ID: 26130065
[TBL] [Abstract][Full Text] [Related]
12. Transfection of T-Box Transcription Factor
Akimoto N; Nakamura K; Hijioka H; Kume K; Matsumura Y; Sugiura T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30453543
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody.
Hamilton DH; Fernando RI; Schlom J; Palena C
Oncotarget; 2015 Mar; 6(7):4853-62. PubMed ID: 25605015
[TBL] [Abstract][Full Text] [Related]
14. The potential role of Brachyury in inducing epithelial-to-mesenchymal transition (EMT) and HIF-1α expression in breast cancer cells.
Shao C; Zhang J; Fu J; Ling F
Biochem Biophys Res Commun; 2015 Nov; 467(4):1083-9. PubMed ID: 26393908
[TBL] [Abstract][Full Text] [Related]
15. Tumor Plasticity and Resistance to Immunotherapy.
Horn LA; Fousek K; Palena C
Trends Cancer; 2020 May; 6(5):432-441. PubMed ID: 32348738
[TBL] [Abstract][Full Text] [Related]
16. BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells.
Sarkar D; Shields B; Davies ML; Müller J; Wakeman JA
Int J Cancer; 2012 Jan; 130(2):328-37. PubMed ID: 21365650
[TBL] [Abstract][Full Text] [Related]
17. The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells.
Fernando RI; Litzinger M; Trono P; Hamilton DH; Schlom J; Palena C
J Clin Invest; 2010 Feb; 120(2):533-44. PubMed ID: 20071775
[TBL] [Abstract][Full Text] [Related]
18. Loss of the Cyclin-Dependent Kinase Inhibitor 1 in the Context of Brachyury-Mediated Phenotypic Plasticity Drives Tumor Resistance to Immune Attack.
Hamilton DH; McCampbell KK; Palena C
Front Oncol; 2018; 8():143. PubMed ID: 29774202
[TBL] [Abstract][Full Text] [Related]
19. The T-box transcription factor Brachyury promotes renal interstitial fibrosis by repressing E-cadherin expression.
Sun S; Sun W; Xia L; Liu L; Du R; He L; Li R; Wang H; Huang C
Cell Commun Signal; 2014 Nov; 12():76. PubMed ID: 25433496
[TBL] [Abstract][Full Text] [Related]
20. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer.
Roselli M; Fernando RI; Guadagni F; Spila A; Alessandroni J; Palmirotta R; Costarelli L; Litzinger M; Hamilton D; Huang B; Tucker J; Tsang KY; Schlom J; Palena C
Clin Cancer Res; 2012 Jul; 18(14):3868-79. PubMed ID: 22611028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
